Intravenous azithromycin plus ceftriaxone followed by oral azithromycin for the treatment of inpatients with Community-Acquired Pneumonia: An open-label, non-comparative multicenter trial

Intravenous azithromycin plus ceftriaxone followed by oral azithromycin for the treatment of inpatients with Community-Acquired Pneumonia: An open-label, non-comparative multicenter trial

Autor Rubio, Fernando Gongora Autor UNIFESP Google Scholar
Cunha, Clovis A. Google Scholar
Lundgren, Fernando L. C. Google Scholar
Lima, Maria P. J. S. Google Scholar
Teixeira, Paulo J. Z. Google Scholar
Oliveira, Julio C. A. Google Scholar
Golin, Valdir Google Scholar
Mattos, Waldo L. L. D. Google Scholar
Maehlmann, Herbert K. Google Scholar
Moreira, Edson D. Google Scholar
Jardim, José Roberto Autor UNIFESP Google Scholar
Silva, Rodney L. F. Google Scholar
Silva, Patricia H. B. Google Scholar
Instituição Hosp Base FUNFARME
Nossa Senhora Gracas Hosp
Otavia Freitas Gen Hosp
Catholic Univ
Irmandade Santa Casa Miseriocordia Porto Alegre
Univ Fed Juiz de Fora
Irmandade Santa Casa Miseriocordia
Nossa Senhora Conceicao Hosp
Gen Hosp Itapecerica Serra OSS Seconci
Gen Hosp Roberto Santos
Universidade Federal de São Paulo (UNIFESP)
Univ Fed Parana
Sanatorinhos Hosp OSS Acao Comunitaria
Resumo Community-Acquired Pneumonia (CAP) is a major public health problem. in Brazil it has been estimated that 2,000,000 people are affected by CAP every year. of those, 780,000 are admitted to hospital, and 30,000 have death as the outcome. This is an open-label, non-comparative study with the purpose of evaluating efficacy, safety, and tolerability levels of IV azithromycin (IVA) and IV ceftriaxone (IVC), followed by oral azithromycin (OA) for the treatment of inpatients with mild to severe CAP. Eighty-six patients ( mean age 56.6 +/- 19.8) were administered IVA (500mg/day) and IVC (1g/day) for 2 to 5 days, followed by AO (500mg/day) to complete a total of 10 days. At the end of treatment (EOT) and after 30 days (End of Study - EOS) the medication was evaluated clinically, microbiologically and for tolerability levels. Out of the total 86-patient population, 62 (72.1%) completed the study. At the end of treatment, 95.2% (CI(95): 88.9% - 100%) reported cure or clinical improvement; at the end of the study, that figure was 88.9% (CI(95): 74.1% - 91.7%). Out of the 86 patients enrolled in the study, 15 were microbiologically evaluable for bacteriological response. of those, 6 reported pathogen eradication at the end of therapy (40%), and 8 reported presumed eradication (53.3%). At end of study evaluation, 9 patients showed pathogen eradication (50%), and 7 showed presumed eradication (38.89%). Therefore, negative cultures were obtained from 93.3% of the patients at EOT, and from 88.9% at the end of the study. One patient (6.67% of patient population) reported presumed microbiological resistance. At study end, 2 patients (11.11%) still reported undetermined culture. Uncontrollable vomiting and worsening pneumonia condition were reported by 2.3% of patients.Discussion and Conclusion Treatment based on the administration of IV azithromycin associated to ceftriaxone and followed by oral azithromycin proved to be efficacious and well-tolerated in the treatment of Brazilian inpatients with CAP.
Assunto community acquired infections
pneumonia
anti-bacterial agents
macrolide ketolides
azithromycin
Idioma Inglês
Financiador Pfizer
Data 2008-06-01
Publicado em Brazilian Journal of Infectious Diseases. Salvador: Contexto, v. 12, n. 3, p. 202-209, 2008.
ISSN 1413-8670 (Sherpa/Romeo, fator de impacto)
Editor Contexto
Extensão 202-209
Fonte http://dx.doi.org/10.1590/S1413-86702008000300008
Direito de acesso Acesso aberto Open Access
Tipo Artigo
Web of Science WOS:000259751400008
SciELO S1413-86702008000300008 (estatísticas na SciELO)
URI http://repositorio.unifesp.br/handle/11600/30681

Mostrar registro completo




Arquivos deste item

Arquivos Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item aparece na(s) seguinte(s) coleção(s)

Buscar DSpace


Navegar

Minha conta